Tesamorelin: A GHRH Analogue With the Strongest Clinical Track Record

Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone (GHRH). Structurally, it preserves the 44 amino acids of native GHRH(1–44) and adds a trans-3-hexenoic acid group at the N-terminus. That single modification dramatically extends the molecule's half-life by protecting it from rapid degradation by dipeptidyl peptidase-4 (DPP-4), while preserving binding affinity at the GHRH receptor in the anterior pituitary.

Tesamorelin is the active ingredient in EGRIFTA®, approved by the U.S. FDA in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — making it one of the very few research peptides in this family with a complete regulatory dossier.

Unlike direct growth hormone administration, tesamorelin acts upstream by stimulating the pituitary to release endogenous growth hormone in a pulsatile pattern. This preserves the body's own feedback loops: when IGF-1 rises sufficiently, somatostatin feedback dampens further GH release. The result is a more physiologic GH/IGF-1 profile than supraphysiologic rhGH dosing typically produces.

In practice, this means tesamorelin elevates 24-hour GH secretion modestly and IGF-1 within or slightly above normal ranges in study populations, rather than producing the very high peak GH levels associated with direct GH injection.

The clinical evidence base for tesamorelin is unusually robust for a peptide outside the conventional small-molecule pipeline. Falutz and colleagues published two pivotal Phase 3 trials in The New England Journal of Medicine and AIDS during 2007–2008, demonstrating that 26 weeks of tesamorelin produced statistically significant reductions in visceral adipose tissue (VAT) measured by CT scan in HIV-infected patients with central fat accumulation. Subsequent extension and pooled-analysis work confirmed that the effect was sustained over 52 weeks and reversed after withdrawal.

Stanley et al. (JAMA, 2014) extended the story by demonstrating that tesamorelin also reduced hepatic fat content, with intrahepatic triglyceride content falling roughly 36% relative to placebo over six months. This pointed to a broader metabolic role beyond visceral fat alone.

Treatment-emergent effects observed across these trials included transient increases in fasting glucose and modest joint-related symptoms — both consistent with the expected pharmacology of elevated GH/IGF-1 axis activity. Long-term safety has not been characterized outside the HIV-lipodystrophy population.

Tesamorelin is supplied lyophilized and is typically stored at -20°C, dry and protected from light. Like other GHRH-family peptides, tesamorelin is sensitive to repeated freeze-thaw cycles, agitation, and elevated temperatures.

This product is supplied strictly for in vitro and preclinical research use. It is not sold for human consumption. Researchers working with tesamorelin should consult original published methodologies for handling protocols.

Tesamorelin is often compared to CJC-1295 and other GHRH analogues. The defining distinction is regulatory: tesamorelin has been studied in randomized, placebo-controlled human trials with imaging-quantified endpoints, while most other GHRH-family peptides have data limited to pharmacokinetic and small open-label studies. For research groups interested in modeling endogenous GH pulsatility with the strongest available human reference data, tesamorelin remains the benchmark molecule.